Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration

Rhea-AI Summary

Accuray's Tomo® C radiation therapy system receives approval in China, expanding access to radiotherapy treatments for cancer patients.

Positive

• Approval of the Tomo C System in China will enable Accuray to expand access to radiotherapy treatments, addressing the high demand for radiation therapy in the country.

Negative

• None.

MADISON, Wis., Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo^® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA). The new, made in China system, is the first joint venture product and represents an important achievement on behalf of cancer patients, many of whom will need treatment with radiotherapy at least once to cure their cancer, increase the chance of cure or relieve symptoms caused by cancer¹.

"The NMPA approval of the Tomo C System represents a tremendous milestone for Accuray and the CNNC-Accuray joint venture. The availability of the new system will enable us to expand access to radiotherapy treatments to cancer patients needing care. Currently, the number of people requiring radiation treatments in China far outweighs the capacity for treatment. In fact, the number of systems that deliver radiation therapy is well below the World Health Organization recommendations," said Suzanne Winter, president and CEO of Accuray. "Through our CNNC-Accuray joint venture we can now offer the Tomo C System, a fast and effective radiation delivery device, to the largest segment of the China market, enabling more medical care teams to provide personalized and highly precise treatments to more people each day."

The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue. The system's unique architecture and high-speed multi-leaf collimator makes it possible for medical care teams to select from a range of delivery modalities, from conventionally fractionated to ultra-hypofractionated treatments, to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations and goals regarding new products, services and innovations, expectations regarding our joint venture, patient experiences and patient outcomes. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on September 7, 2023, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan
Public Relations Director, Accuray  
+1 (408) 789-4426 
bkaplan@accuray.com                                                    

 

¹ https://www-pub.iaea.org/MTCD/Publications/PDF/P1638_web.pdf

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-medical-products-administration-301944172.html

SOURCE Accuray Incorporated